StockData

Kura Oncology vs Nuvation Bio

KURA and NUVB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KURA and NUVB compare

Nuvation Bio is the larger company, worth 2.1 times as much as Kura Oncology ($1.4B against $666M).

Nuvation Bio keeps more of each dollar of sales as profit, with a net margin of −88.2% compared with −369% at Kura Oncology.

Nuvation Bio scores higher on the StockData Score (4 against 1 for Kura Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKURANUVB
Size and price
Market cap$666M$1.4B
Share price$7.49$3.90
Change, 1 year−33.2%−19.8%
Change, 5 years−46.5%−52.3%
Beta (5Y)2.301.77
Employees260298
StockData Score
Total score14 (better)
Valuation score00
Growth score01 (better)
Performance score01 (better)
Health score12 (better)
Dividend score00
Valuation
P/S8.4×8.1× (better)
P/B37.1×5.4× (better)
FCF yield−13.4%–
Fair value–$1.89
Margin of safety–−107%
Growth
Revenue growth (TTM)–1084%
Profitability
Operating margin−394%−81.0% (better)
Net margin−369%−88.2% (better)
FCF margin−112%–
Return on equity−225%−47.8% (better)
Financial health
Debt / equity0.550.02 (better)
Interest coverage−227.1×−5.4× (better)
Current ratio3.608.37 (better)
Altman Z-score−3.560.12 (better)
Piotroski F-score14 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions98.0%66.5%
Held by insiders2.7%24.6%
Insider net buying, 12 months$512K (better)−$4.5M
Superinvestors holding–2
Short interest, % of float14.6%23.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.